Ireland· IE-PA-EU/1/14/947/001-004
Xultophy 100 units/mL + 3.6 mg/mL solution for injection.
A drugs used in diabetes product containing insulin degludec + liraglutide, registered in Ireland by Novo Nordisk A/S.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Insulin degludec + Liraglutide
- Manufacturer
- Novo Nordisk A/S
- Country
- Ireland (IE)
- ATC code
- A10
- ATC class
- DRUGS USED IN DIABETES
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/14/947/001-004
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin degludec + liraglutide in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXULTOPHYNovo Nordisk A/S, Bagsvaerd
- NorwayXultophyOrifarm AS
- SpainXULTOPHY 100 U/ML + 3,6 MG/ML SOLUCION INYECTABLENovo Nordisk A/S
- FinlandXultophyNovo Nordisk A/S
- FranceXULTOPHY 100 unités/ml + 3,6 mg/ml, solution injectableNOVO NORDISK (DANEMARK)
- United KingdomXultophy 100units/ml / 3.6mg/ml solution for injection 3ml pre-filled pensNovo Nordisk Ltd
- IcelandXultophyNovo Nordisk A/S*
- NetherlandsXultophy 100 eenheden/ml + 3,6 mg/ml oplossing voor injectieNovo Nordisk A.S.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Xultophy
- Norway · Xultophy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cec344ee-ad08-4c6b-9c92-0679fa4dd676 GET /v1/drugs/cec344ee-ad08-4c6b-9c92-0679fa4dd676?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"A10"
],
"strength": null,
"pa_number": "EU/1/14/947/001-004",
"substances": [
"Insulin degludec",
"Liraglutide"
],
"legal_basis": "Fixed combination application (Article 10b of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "18/09/2014",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about insulin degludec + liraglutide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.